Maravai LifeSciences refinances credit, cuts debt to $150M and extends maturity to 2032
What's the deal? Maravai LifeSciences (NASDAQ: MRVI), a provider of life science reagents and services to biotech researchers, has refinanced its credit agreement. The company secured US$97.1M term loan and US$19.4M revolving credit facility, using the new loan plus $98.5M in cash to pay off its prior debt.
The move cuts Maravai's total outstanding principal from roughly $243M to $150M and pushes the maturity date from October 2027 to June 2032.
Why now? The prior credit agreement was due in just over two years. By refinancing now, Maravai locks in a longer runway and a more flexible credit structure while it still has nearly $100M in cash to put toward debt reduction.
"This refinancing is a sign of our financial strength and positions the Company for long-term success," said chief financial officer Raj Asarpota.
What could go wrong? Maravai used a substantial chunk of its cash reserves to pay down debt. If revenue growth stalls or the broader biotech sector hits turbulence, the company could face tighter liquidity despite the new revolving facility. The terms of the new credit agreement — including interest rates — have not been disclosed publicly beyond SEC filings.
The signal: Maravai, classified by Dealroom as a late-growth-stage company, is making the kind of balance-sheet move typical of life sciences firms bracing for a prolonged funding winter in biotech — trading near-term cash for longer-dated, more flexible debt. Cutting roughly 38% of its outstanding principal while pushing maturity out five years gives the nucleic acid synthesis specialist breathing room to ride out sector headwinds without needing to tap equity markets at a discount.
Read more: MarketScreener
